Point72 Asset Management’s BridgeBio Pharma BBIO Stock Holding History

Point72 Asset Management’s Portfolio BBIO Stock Details BBIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.75M	Buy	23,600 +19,800	+521%	+$1.44M	﹤0.01%	2403
2025 Q4	$291K	Buy	+3,800	New	+$249K	﹤0.01%	3489
2025 Q2	–	Sell	-30,000	Closed	-$1.04M	–	2183
2025 Q1	$1.04M	Sell	30,000 -30,000	-50%	-$1.01M	﹤0.01%	1435
2024 Q4	$1.65M	Buy	60,000 +25,000	+71%	+$646K	﹤0.01%	1312
2024 Q3	$891K	Buy	+35,000	New	+$919K	﹤0.01%	1461
2024 Q1	–	Sell	-50,000	Closed	-$2.02M	–	2183
2023 Q4	$2.02M	Buy	+50,000	New	+$1.5M	﹤0.01%	1201
2023 Q2	–	Sell	-35,000	Closed	-$580K	–	2182
2023 Q1	$580K	Buy	+35,000	New	+$408K	﹤0.01%	1207
2022 Q1	–	Sell	-52,200	Closed	-$871K	–	1173
2021 Q4	$871K	Buy	+52,200	New	+$2.21M	﹤0.01%	932

Other funds holding BBIO

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

KKRC

Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

DAM

Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return

ACM

Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Point72 Asset Management's BBIO Position: Q2 2025 in Review

Point72 Asset Management sold out of BridgeBio Pharma (BBIO) in Q2 2025, closing a stake of 198,780 shares — an estimated $6.87M sold.

Point72 Asset Management first reported a position in BBIO in Q2 2019 and held it in 6 quarters. The position peaked at $6.87M in Q1 2025. 359 funds tracked by Wall St. Rank hold BBIO as of Q2 2025.

Point72 Asset Management reported no remaining BridgeBio Pharma position as of Q2 2025 after selling out during the quarter.
Point72 Asset Management sold 198,780 BridgeBio Pharma shares in Q2 2025, an estimated $6.87M.
Point72 Asset Management first reported a position in BridgeBio Pharma in Q2 2019 and held it in 6 quarters.
Point72 Asset Management's BridgeBio Pharma position peaked at $6.87M in Q1 2025.
359 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q2 2025.

Based on Point72 Asset Management's 13F filing for Q2 2025, filed 14 Aug 2025.